Peginterferon Alfa-2A

證據等級: L5

預測適應症: 10 個

PEGINTERFERON ALFA-2A: From Chronic Hepatitis C to Hepatitis B Virus Infection

One-Sentence Summary

Peginterferon alfa-2a (Pegasys) is a pegylated interferon originally developed and marketed for chronic hepatitis C. The TxGNN model predicts it is effective for Hepatitis B Virus Infection, supported by 50 clinical trials and 20 publications — and the underlying evidence indicates this is largely a confirmation of an already globally approved indication rather than a purely novel repurposing hypothesis.

Quick Overview

Item	Content
Original Indication	Chronic Hepatitis C (well-established global use; the evidence pack itself has a data gap on this field — see note below)
Predicted New Indication	Hepatitis B Virus Infection
TxGNN Prediction Score	99.94%
Evidence Level	L1
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Note on Original Indication: The evidence pack’s original_indications and Danish licence fields are both empty (Data Gap DG001/DG002). The “Chronic Hepatitis C” original indication above reflects well-established public pharmacological knowledge about peginterferon alfa-2a (Pegasys), not a value extracted from this evidence pack. This should be confirmed against the official Danish/EU SmPC before use in any regulatory context.

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available from DrugBank for this evidence pack (Data Gap DG002). Based on known pharmacology, peginterferon alfa-2a is a pegylated form of recombinant interferon alfa-2a that activates the JAK-STAT signalling pathway, inducing host innate antiviral responses (interferon-stimulated gene expression) as well as immunomodulatory effects. This mechanism underlies its antiviral activity against hepatotropic viruses broadly, including both HCV and HBV.

Chronic hepatitis C and chronic hepatitis B are both hepatotropic viral infections sharing a common therapeutic rationale for interferon-based immune activation: suppression of viral replication and promotion of host immune clearance (for HBV, specifically HBeAg seroconversion and HBsAg loss).

Importantly, the repurposing rationale in the evidence pack notes that this is not a purely speculative old-drug-new-use candidate: peginterferon alfa-2a (Pegasys) already holds regulatory approval for chronic hepatitis B in numerous countries worldwide. The “[Data Gap]” in the original_indications field appears to be a data-completeness issue in this evidence pack rather than evidence that no hepatitis B indication exists. This distinction matters for how the “Proceed with Guardrails” recommendation should be interpreted — the clinical/scientific case is strong; what is missing is Denmark-specific regulatory documentation (SmPC, licence status, DDI data).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01095835	Phase 3	Completed	131	RCT comparing 48 vs 96 weeks of 40kD PEG-IFN alfa-2a, alone or with lamivudine, in HBeAg-negative chronic HBV
NCT01011738	N/A (observational)	Completed	1,842	Large prospective, non-interventional cohort evaluating on-treatment predictors of response to Pegasys in HBeAg-positive/negative CHB
NCT04667104	Phase 2	Completed	48	JNJ-73763989 + JNJ-56136379 + nucleos(t)ide analogue + PegIFN-alfa2a combination in virologically suppressed chronic HBV
NCT01086085	Phase 4	Completed	265	Response-guided treatment (RGT) optimisation of Pegasys in HBeAg-positive CHB, quantitative HBsAg reduction
NCT00940485	Phase 4	Completed	200	Combination/sequential Pegasys + entecavir for optimising HBeAg seroconversion
NCT01373684	Phase 4	Completed	90	Add-on PEG-IFN alfa-2a to nucleos(t)ide analogue therapy to induce HBsAg decline in HBeAg-negative CHB
NCT02570191	Phase 4	Completed	60	Efficacy, safety and tolerability of Pegasys in HBeAg-negative chronic HBV
NCT01734018	N/A (observational)	Completed	50	Multicentre, prospective, non-interventional study of Pegasys response parameters in HBeAg-positive/negative CHB
NCT02732639	Phase 3	Completed	31	Pegasys monotherapy (48 weeks) in chronic hepatitis D (HBV/HDV co-infection)
NCT06092333	Phase 2	Recruiting	50	Ongoing pilot combining VIR-2218 with peginterferon alfa-2a for chronic hepatitis B

(Full evidence pack contains 50 registered trials for this indication; the above 10 were selected for phase, completion status, and direct HBV relevance.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15987917	2005	RCT	New England Journal of Medicine	Landmark trial: peginterferon alfa-2a ± lamivudine vs lamivudine alone in HBeAg-positive chronic hepatitis B
30865588	2019	Systematic Review / Meta-analysis	Antiviral Therapy	Individual participant data meta-analysis establishing PEG-IFN stopping rules in chronic hepatitis B
30549279	2019	RCT	Hepatology	Entecavir + peginterferon alfa-2a in HBeAg-positive immune-tolerant adults with chronic HBV
30318613	2019	RCT (paediatric)	Hepatology	Entecavir/peginterferon alfa-2a combination in HBeAg-positive immune-tolerant children with chronic HBV
29689122	2018	Phase III RCT	Hepatology	PEG-B-ACTIVE study: peginterferon alfa-2a in children 3–<18 years with chronic hepatitis B
29715359	2018	Review	JAMA	Overview of chronic hepatitis B infection, epidemiology and progression risk
21423260	2011	Review	Nature Reviews Gastroenterology & Hepatology	Review of hepatitis B therapy goals and treatment response markers
26700861	2015	Cohort	Virology Journal	Long-term effects of peginterferon alfa-2a therapy in Japanese chronic hepatitis B patients
41312046	2025	Review	Drug Design, Development and Therapy	PEG-IFN-α-induced functional cure in special populations with chronic HBV — current trends and challenges
19084016	2009	Study	Gastroenterology	Peginterferon alfa-2a plus ribavirin for dual chronic HBV/HCV infection

Denmark Market Information

No marketing authorisation is currently registered for peginterferon alfa-2a in this dataset — taiwan_regulatory.total_licenses = 0 and market_status = Not marketed. No national (Laegemiddelstyrelsen) or centralised (EMA) authorisation records were returned for this evidence pack. This should be independently verified against the EMA/EU medicines database, since peginterferon alfa-2a (Pegasys) is known to hold centralised EU marketing authorisation historically — the absence of a record here likely reflects a data-collection gap rather than confirmed non-authorisation.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. (All safety fields in this evidence pack — key warnings, contraindications, and drug-drug interactions — returned as data gaps or “not found”; DG001 is flagged as a Blocking gap for safety initial assessment.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

Evidence level L1 is met (≥2 completed Phase 3 RCTs: NCT01095835 and the 2005 NEJM trial by Lau et al.), and the therapeutic rationale is exceptionally strong because peginterferon alfa-2a already holds hepatitis B indications in multiple jurisdictions globally — this is corroboration of an established use, not a speculative hypothesis.
However, Denmark-specific regulatory data (SmPC warnings/contraindications, marketing authorisation status, DDI profile) are all missing (DG001 – Blocking), which prevents a full safety sign-off and unconditional “Go”.
For context, the model also surfaced several lower-confidence signals for this drug (hepatitis E virus infection — Research Question stage, evidence level L3; and hepatitis A virus infection, an MeSH “animal hepatitis” term, and Omsk haemorrhagic fever — all flagged Hold as likely knowledge-graph noise with no genuine supporting evidence). These were screened out and are not part of this recommendation.

To proceed, the following is needed:

Danish/EU SmPC warnings, precautions, and contraindications (DG001, Blocking)
Confirmed mechanism-of-action documentation via DrugBank API (DG002, High)
Verification of actual Danish/EU marketing authorisation status (current record shows 0 licences, which should be cross-checked against EMA’s centralised procedure database)
A proper drug-drug interaction (DDI) screen, since the current query returned “not_found”
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.